Pharmaceutical composition comprises (separately or in combination): (A) a non-sedating antihistamine (or its salt), other than compounds of the loratadine type； (B) a leukotriene antagonist (or its salt) comprising (B1) leukotriene D 4 antagonists, (B2) 5-lipoxygenase inhibitors or (B3) FLAP (5-lipoxygenase activating protein) antagonists； and (C) conventional carriers and/or extenders or auxiliaries. Independent claims are included for the following: (i) the use of a combination of (A)-(C) for the preparation of a medicament for use as above； (ii) a medicament comprising (A)-(C), for use as above； and (iii) the preparation of the medicaments, by mixing and formulating the appropriate components. - ACTIVITY : Antiallergic； antiinflammatory； ophthalmological. In tests for inhibition of ovalbumin-induced nasal mucosal permeability in sensitized rats, the degree of inhibition was 11% using azelastine alone at 0.01 mg/kg i.p., 7% using montelukast alone at 0.1 mg/kg i.p. and 40% using a combination of azelastine at 0.01 mg/kg i.p. and montelukast at 0.1 mg/kg i.p. - MECHANISM OF ACTION : Antihistamine； leukotriene D 4 antagonist； 5-lipoxygenase inhibitor； FLAP (5-lipoxygenase activating protein) antagonist.
